Elanco executive joins Neurizon board as observer

Neurizon Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) announced the appointment of Justine Conway as a board observer. Conway serves as Global Head of Business Development at Elanco Animal Health (NYSE: ELAN).

The appointment follows an exclusive global license agreement between the companies for Monepantel, the active pharmaceutical ingredient in Neurizon's NUZ-001 drug candidate, announced in July 2025. The agreement provides Neurizon access to animal safety data and manufacturing data needed for clinical trials and potential regulatory approvals.

Conway brings over 20 years of experience in healthcare and animal health industries. She joined Elanco in 2020 after working in investment banking at Macquarie Bank and Bank of America Merrill Lynch in Sydney, London and New York. Her background includes pharmaceutical and biotech sector experience, executing mergers and acquisitions transactions and capital raisings.

As board observer, Conway will attend and participate in board and committee meetings but will not hold voting rights. The Melbourne-based biotech company said her expertise will support advancement of NUZ-001 toward late-stage development and entry into the HEALEY ALS Platform Trial this quarter.

"Justine's appointment as Board Observer strengthens an already highly productive partnership with Elanco and brings exceptional global expertise into Neurizon's governance framework," said Non-Executive Chairman Sergio Duchini.

Neurizon is developing NUZ-001 as a treatment for amyotrophic lateral sclerosis, the most common form of motor neuron disease. The drug candidate remains investigational and is not approved for commercial use in any jurisdiction.

You May Also Be Interested In

• Goldman Sachs Upgrades Plains All American (PAA) to Neutral
• Beyond Meat director resigns from board after seven months
• IGT parent company appoints Patrick Ramsey to board